Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation Therapy with or without Short-Course Hormone Therapy in Intermediate Risk Prostate Cancer
NCT00388804Phase 3Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2005
- Primary completion
- Apr 2011
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leuprolide, goserelin, bicalutamide and flutamide in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2005; status: terminated.
02
Drugs
leuprolidegoserelinbicalutamideflutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00388804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00388804.